An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
ARGENX BV
Portal de investigación